Wedbush Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock Price

Revolution Medicines (NASDAQ:RVMD) had its target price raised by Wedbush from $201.00 to $225.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s target price points to a potential upside of 2.81% from the company’s previous close.

A number of other analysts also recently commented on the stock. Wolfe Research reissued an “outperform” rating and set a $220.00 price objective on shares of Revolution Medicines in a report on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a report on Friday, July 17th. Guggenheim upped their price target on Revolution Medicines from $235.00 to $240.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Truist Financial raised their price objective on Revolution Medicines from $231.00 to $239.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Mizuho lifted their price objective on Revolution Medicines from $185.00 to $215.00 and gave the stock an “outperform” rating in a report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $174.39.

Revolution Medicines Trading Up 1.6%

NASDAQ:RVMD opened at $218.86 on Thursday. Revolution Medicines has a 1 year low of $37.56 and a 1 year high of $220.34. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. The stock has a fifty day moving average price of $191.27 and a two-hundred day moving average price of $147.30. The stock has a market capitalization of $46.91 billion, a price-to-earnings ratio of -24.85 and a beta of 1.39.

Revolution Medicines (NASDAQ:RVMD) last issued its earnings results on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same period in the prior year, the firm posted ($1.31) EPS. As a group, sell-side analysts anticipate that Revolution Medicines will post -8.82 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Sushil Patel sold 5,580 shares of Revolution Medicines stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $187.99, for a total transaction of $1,048,984.20. Following the completion of the sale, the director owned 21,656 shares in the company, valued at approximately $4,071,111.44. This trade represents a 20.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Stephen Michael Kelsey sold 4,175 shares of Revolution Medicines stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $156.12, for a total value of $651,801.00. Following the sale, the insider owned 291,876 shares of the company’s stock, valued at approximately $45,567,681.12. This represents a 1.41% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 212,497 shares of company stock valued at $38,206,486. Insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Revolution Medicines

Several hedge funds have recently modified their holdings of the company. HighTower Advisors LLC grew its holdings in shares of Revolution Medicines by 311.2% during the second quarter. HighTower Advisors LLC now owns 10,485 shares of the company’s stock worth $1,964,000 after buying an additional 7,935 shares in the last quarter. California State Teachers Retirement System raised its position in shares of Revolution Medicines by 26,920.9% in the second quarter. California State Teachers Retirement System now owns 44,659,351 shares of the company’s stock valued at $8,363,803,000 after buying an additional 44,494,074 shares during the last quarter. Washington Trust Advisors Inc. purchased a new position in shares of Revolution Medicines during the second quarter valued at approximately $90,000. Readystate Asset Management LP boosted its position in Revolution Medicines by 18.5% during the second quarter. Readystate Asset Management LP now owns 37,727 shares of the company’s stock worth $7,066,000 after acquiring an additional 5,880 shares during the last quarter. Finally, Ameritas Advisory Services LLC acquired a new stake in Revolution Medicines during the second quarter worth approximately $48,000. 94.34% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approves RASONQUE: The FDA approved RASONQUE (daraxonrasib), Revolution Medicines’ oral RAS-targeted therapy, for adults with previously treated metastatic pancreatic ductal adenocarcinoma or patients unable to receive combination chemotherapy. The company describes it as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, creating a significant commercial opportunity in a disease with limited treatment options. FDA approval announcement
• Positive Sentiment: Commercial launch and pricing established: Revolution Medicines priced RASONQUE at approximately $39,800 per month, providing investors with an initial benchmark for potential sales and reimbursement economics. Rapid FDA approval also shortens the path from clinical development to revenue generation. RASONQUE pricing article
• Positive Sentiment: Analyst support increased: TD Cowen upgraded RVMD, adding to an already favorable analyst backdrop. Recent firms including Oppenheimer, Truist Financial, RBC and Needham have maintained Buy or Outperform ratings and raised price targets, reinforcing confidence in the drug’s launch and broader RAS-inhibitor pipeline. TD Cowen upgrade
• Neutral Sentiment: Stock already reflects substantial optimism: RVMD has risen sharply over the past year and is trading close to its $220.34 12-month high, with a market capitalization of about $46 billion. Investors may therefore demand strong launch execution and sales growth to justify the current valuation.
• Negative Sentiment: High price could weigh on adoption: The nearly $40,000 monthly list price has prompted concerns that payer negotiations, reimbursement hurdles or affordability issues could slow uptake, which may explain why investor enthusiasm has been more measured despite the approval. Drug pricing concerns
• Negative Sentiment: Insider selling: Director Mark Goldsmith sold 80,000 shares for approximately $16.7 million, reducing his holdings by about 23%. The sale does not change the company’s fundamentals but may create a modest sentiment overhang, particularly after the stock’s substantial advance. Insider sale report

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.